News

Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Yahoo·08:00ABT▼−1.1%

Abbott: Demand Headwinds And Litigation Risks Priced-In - Spin-Off Tailwinds Ahead

Abbott Laboratories has hinted at a softer FQ4'26 performance in the recent FQ3'26 earnings call. Read why ABT stock is a buy.

SeekingAlpha·06:00ABT▼−1.1%

Argus Research Downgrades Abbott Laboratories to Hold

Argus Research analyst David Round downgrades Abbott Laboratories (NYSE:ABT) from Buy to Hold.

Benzinga·04:34ABT▼−1.1%

Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment

For many people with cancer, completing treatment can bring a new uncertainty: Is my cancer really gone?

Yahoo·09:00ABT▼−1.1%

Abbott Announces Commercial Availability Of Oncodetect Molecular Residual Disease Test

Abbott (NYSE: ABT) today announced the commercial availability of its next-generation Oncodetect® MRD test, a personalized, tumor-informed, whole-genome sequencing test designed to provide molecular insights during and

Benzinga·05:08ABT▼−1.1%

Abbott Laboratories: A New Growth Story Takes Shape

Abbott Laboratories remains a Buy, driven by robust device and diagnostics growth and the strategic spin-off of its Nutrition business. Learn more about ABT stock here.

SeekingAlpha·03:50ABT▼−1.1%

Abbott Laboratories (ABT) Posted Higher Sensitivity Data For Colorectal Cancer Recurrence Detection

Abbott Laboratories (NYSE:ABT) reported new Beta-CORRECT study data on its Oncodetect test at ESMO 2026. The Beta-CORRECT trial showed a significant sensitivity improvement for detecting colorectal cancer recurrence using circulating tumor DNA. The Oncodetect assay targets low levels of tumor DNA in the bloodstream to support closer monitoring of patients after colorectal surgery. The sensitivity gains for Oncodetect in the Beta-CORRECT study are important, but investors should weigh them...

Yahoo·06:13ABT▼−1.1%

Pacemakers Market Forecasts Growth from $5.4 Billion (2025) to $7.5 Billion by 2030, Profiling Medtronic, Abbott, Boston Scientific, Biotronik & 6 Other Key Players

108-Page Report Examines the Shift to Leadless and MRI-Compatible Devices as Rising Arrhythmia Prevalence Drives Demand, While High Procedure Costs, Strict Approvals and Cybersecurity Risks Weigh on GrowthDublin, Oct. 23, 2026 (GLOBE NEWSWIRE) -- "Pacemakers: Global Markets" has been added to ResearchAndMarkets.com's offering. The report delivers a comprehensive analysis of the global pacemakers market, covering revenue performance, growth prospects, technology developments, regulatory condition

Yahoo·10:02ABT▼−1.1%

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

For patients with colorectal cancer, surgery can remove visible cancer, but it can be difficult to know whether minute traces of the disease remain. Abbott (NYSE: ABT) today announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequencing (WGS)-based Oncodetect® molecular residual disease (MRD) test achieved a 30-percent absolute improvement in sensitivity for colorectal cancer recurrence within two years of surgery,

Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $120

Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $119 to $120.

Benzinga·06:17ABT▼−1.1%

Abbott's New Beta-CORRECT Data At ESMO Congress Demonstrates 30% Enhancement In Sensitivity For Colorectal Cancer Recurrence Within Two Years Of Surgery

Abbott (NYSE:ABT) today announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequencing (WGS)-based Oncodetect® molecular residual disease

Benzinga·05:17ABT▼−1.1%

Catheter Precision Announces Publication of Comparative Study Showing LockeT Outperforms Abbott’s Perclose Internal Vascular Closure Device

FORT MILL, S.C, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, a wholly owned subsidiary of Flyte Aviation, Inc. (NYSE American: VJET), today announced the first published comparative study evaluating its LockeT suture retention device against a traditional internal vascular closure device (VCD) following large bore venous access. The 172-patient peer-reviewed study, titled "Vascular closure with a suture retention device versus suture-mediated closure system after large bore venous acces

Yahoo·16:54ABT▼−1.1%

Citigroup Maintains Buy on Abbott Laboratories, Lowers Price Target to $122

Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $125 to $122.

Benzinga·11:20ABT

Australia Bionic Devices Market Size, Share, Growth, and Forecast 2026-2034 Featuring Profiles of Cochlear, Medtronic Australasia, Edwards Lifesciences Australia, Baxter Int'l, Boston Scientific Corp., Abiomed Australia, Abbott Labs

Dublin, Oct. 22, 2026 (GLOBE NEWSWIRE) -- "Australia Bionic Devices Market Report by Product, Fixation, Technology, End User, States and Companies Analysis 2026-2034" has been added to ResearchAndMarkets.com's offering. According to the report, the market is expected to increase from US$ 117.32 Million in 2025 to US$ 248.98 Million in 2034, registering a CAGR of 8.72% during 2026-2034. Growth is being driven by the expanding use of cochlear implants, advanced prosthetics, neurostimulation system

Yahoo·10:35ABT▼−1.1%

India regulator pulls up Nestlé, Abbott over infant-formula violations

The FSSAI issued a notice to Nestlé India concerning its Lactogen Pro 1 Powder, seeking scientific substantiation for whey protein claims.

Yahoo·10:12ABT

Abbott's Q3 Earnings Call Focuses on Nutrition Spin-Off and Outlook

Abbott plans to spin off its $8.5B Nutrition business by 2027 while cutting its 2026 sales growth outlook amid diabetes pricing and electrophysiology challenges.

Yahoo·09:00ABT▼−1.1%

Abbott to spin-off nutrition into standalone business

The US group said the decision addresses “different investment identities and requirements, growth profiles, and innovation cycles”.

Yahoo·07:03ABT▼−1.1%

TD Cowen Maintains Buy on Abbott Laboratories, Lowers Price Target to $118

TD Cowen analyst Joshua Jennings maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $135 to $118.

Benzinga·05:31ABT▼−1.1%

Baird Maintains Outperform on Abbott Laboratories, Raises Price Target to $123

Baird analyst David Rescott maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $121 to $123.

Benzinga·03:20ABT▼−1.1%

BTIG Maintains Buy on Abbott Laboratories, Lowers Price Target to $125

BTIG analyst Marie Thibault maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $134 to $125.

Benzinga·02:04ABT▼−1.1%

How To Earn $500 A Month From Abbott Stock Ahead Of Q3 Earnings

Abbott Laboratories will release its third-quarter earnings report before the opening bell on Wednesday, Oct. 21. Analysts expect the company to report quarterly earnings of $1.41 per share, up from $1.30 per share in the year-ago period. The consensus estimate...

Yahoo·18:30ABT▼−1.1%

Abbott: 3 Key Takeaways for Long-Term Investors

Pulsed field ablation and expanded cancer screening tools position the core business for accelerated growth beyond historical rates.

Yahoo·16:35ABT▼−1.1%

Abbott (ABT) Q3 2026 Earnings Call Transcript

Abbott plans nutrition spinoff by end of 2027 amid strong Q3 growth.

Yahoo·14:42ABT▼−1.1%

What Abbott Laboratories (ABT) Said on Its Q3 Earnings Call

Abbott Laboratories (NYSE:ABT) reported third-quarter sales growth of 7% and adjusted earnings-per-share growth of 9%, while announcing plans to separate its nutrition business into an independent publicly traded company through a tax-free distribution to shareholders. Chairman and Chief Executive

Yahoo·13:04ABT▼−1.1%

Abbott Laboratories Q3 2026 Earnings Call Summary

Moby summary of Abbott Laboratories's Q3 2026 earnings call

Yahoo·12:49ABT▼−1.1%

Abbott plans to spin out its nutrition business

Abbott, which also cut its 2026 sales growth guidance, said company sales will total $42 billion following the separation.

Yahoo·12:45ABT▼−1.1%

Abbott Laboratories plans to spin off nutrition business, following years of tumult over infant formulas

Abbott Laboratories plans to spin off its nutrition business into a separate company – a move that follows years of tumult over its infant formulas. The new business will sell Abbott products including Similac, PediaSure, Pedialyte, Glucerna and Ensure. The north suburban-based company also makes medical tests, medical devices and generic pharmaceuticals. The new company is expected to have ...

Yahoo·11:03ABT▼−1.1%

Abbott Yo-Yoes On 'Choppy' Third Quarter As A Key Spinoff Looms

Abbott stock yo-yoed early Wednesday on "choppy" third-quarter metrics and lowered sales growth expectations.

Yahoo·10:01ABT▼−1.1%

Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027

Abbott Laboratories (NYSE:ABT) has announced plans to spin off its Nutrition division into a separate publicly traded company, with the transaction expected to be completed by the end of 2027, subject to regulatory and corporate approvals. The proposed separation would create an independent business focused on nutritional products while allowing Abbott to concentrate on its medical devices, diagnostics and established pharmaceuticals operations.

Yahoo·09:47ABT▼−1.1%

Abbott Stock Falls 4% on Similac Spinoff: It’s Shedding Its Slowest Business, but Who Keeps the Lawsuits?

Abbott Laboratories (ABT:NYSE) shares fell more than 4% before the bell on October 21 after the company said it will spin off its Nutrition business, home of Similac, Pedialyte and Ensure, into a separate public company by the end of 2027. The unit brings in about $8.

Yahoo·09:36ABT

Abbott Topples After Announcing Plans To Spin Off Its Nutrition Business

Abbott stock took a hit Wednesday after the healthcare company said it plans to spin off its nutrition business.

Yahoo·08:55ABT▼−1.1%

Abbott Laboratories’s (NYSE:ABT) Q3 2026 earnings results: revenue in line with expectations

Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 2026, with sales up 14.5% year on year to $13.01 billion. Its non-GAAP profit of $1.42 per share was in line with analysts’ consensus estimates.

Yahoo·08:37ABT▼−1.1%

Abbott: Q3 Earnings Snapshot

(AP) — Abbott Laboratories (ABT) on Wednesday reported third-quarter net income of $920 million.On a per-share basis, the Abbott Park, Illinois-based company said it had profit of 53 cents.

Yahoo·07:40ABT▼−1.1%

Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2026.

Yahoo·07:30ABT▼−1.1%

Abbott Laboratories (ABT) Secures Europe CE Mark For Colorectal Cancer Test

Abbott Laboratories (NYSE:ABT) received CE Mark for its Cologuard Plus colorectal cancer test under the EU In Vitro Diagnostic Regulation. The approval clears Abbott to offer the noninvasive stool based screening test in select European markets for colorectal cancer detection. The Cologuard Plus authorization expands Abbott's diagnostics toolkit in Europe and broadens its potential customer base in cancer screening. The Cologuard Plus CE Mark is important, yet Abbott's broader healthcare...

Yahoo·15:09ABT▼−1.1%

Abbott Laboratories Earnings Ahead: What Past Reactions Say About The Stock

Abbott Laboratories (NYSE:ABT) is scheduled to report its earnings on Wednesday, October 21, 2026. The company has a market value of about $181.1 billion. Over the last twelve months it generated $46.6 billion in revenue and $7.3 billion in operating profit, with net income of $5.4 billion.

Yahoo·13:39

Abbott (ABT): Can Libre Keep Growing as Glucose Monitoring Becomes More Competitive?

Abbott Laboratories (NYSE:ABT) benefits each time a patient replaces a glucose sensor. Continuous glucose monitoring, or CGM, sales grew 9.5% excluding currency effects in the second quarter of 2026, versus 7.6% in the first quarter. The investment question is whether repeated purchases can sustain profitable growth as competitors improve their products and insurers influence patient […]

Yahoo·12:31ABT▼−1.1%

The Zacks Analyst Blog Highlights Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services

Healthcare and waste management offer long-term demand opportunities beyond AI in 2027, with Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services in focus.

Yahoo·07:49ABT1.1%

U.S. Wireless Cardiac Monitoring Systems Market Size, Share, and Forecast 2026-2033 Featuring Profiles of Philips, iRhythm Technologies, Abbott, Medtronic, Biotronik (Teleflex) and More

Expanding reimbursement, telehealth integration, and AI-enabled wearables accelerate outpatient and home-based cardiac monitoring adoptionDublin, Oct. 20, 2026 (GLOBE NEWSWIRE) -- "U.S. Wireless Cardiac Monitoring Systems Market Size, Share & Trends Analysis Report by Test Type, Product Type, Indication, End Use, Payer Type, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering. The U.S. wireless cardiac monitoring systems market was valued at an estimated USD 2.4

Yahoo·05:10ABT▼−1.1%

How To Earn $500 A Month From Abbott Stock Ahead Of Q3 Earnings

Abbott expects Q3 EPS of $1.41 and $12.99B revenue. Its 2.42% dividend requires about $247,767 invested to generate $500 monthly.

Benzinga·04:44ABT

Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q3 Earnings

Abbott reports Q3 earnings Oct. 21; analysts expect $1.41 EPS and $12.99B revenue. FDA approved CardioMEMS updates.

Benzinga·03:23ABT▼−1.1%

Tamboran Resources appoints Todd Abbott managing director as Beetaloo moves into development

Tamboran Resources Corporation (NYSE:TBN, ASX:TBN, OTC:TBNRL, FRA:O8R) has appointed chief executive officer (CEO) Todd Abbott as managing director as the company moves from appraisal into development of its Beetaloo Basin gas assets in the Northern Territory. The appointment takes effect on...

Yahoo·18:52ABT▼−1.1%

Abbott Laboratories (ABT) Launches Ensure Max Protein As Undervalued View Faces A Fresh Test

Abbott Laboratories (ABT) just introduced Ensure Max Protein 3-in-1 Muscle Support, a powder that combines protein, creatine and HMB in a single product, putting its nutrition business back in focus for investors. Recent trading suggests interest in Abbott Laboratories is picking up again, with a 7-day share price return of 6.28% and a 90-day share price return of 3.97%. This is occurring even though the year-to-date share price return is down 15.71% and the 1-year total shareholder return...

Yahoo·10:09ABT▼−1.1%

Countdown to Abbott (ABT) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Beyond analysts' top-and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.

Yahoo·08:15ABT

TD Cowen Reiterates Buy on Abbott Laboratories, Maintains $135 Price Target

TD Cowen analyst Joshua Jennings reiterates Abbott Laboratories (NYSE:ABT) with a Buy and maintains $135 price target.

Benzinga·06:02ABT▼−1.1%

Medtronic Pays More Today. Abbott Raises Its Dividend Faster. Which Stock Wins?

Both are Dividend Kings with decades of consecutive raises, but Medtronic and Abbott reward income investors in fundamentally different ways, and choosing the wrong one in retirement could cost you more than you expect.

Yahoo·08:15ABT▼−1.1%

Abbott Laboratories (ABT) Is A Key Player In Closed Loop Neurostimulation

Abbott Laboratories (NYSE:ABT) has been identified as a leading group advancing closed-loop neurostimulation in bioelectronic medicine devices. The company is highlighted for closed-loop neurostimulation systems that interact with neural signals to modulate treatment in real time. This focus on bioelectronic medicine complements Abbott's existing work in cardiac and diabetes devices targeting chronic and neurological conditions. The recognition of Abbott's closed-loop neurostimulation push...

Yahoo·21:16ABT▼−1.1%